Walleye Capital
BDTX icon

Walleye Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Walleye Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-68,016
Closed -$146K – 4267
2024
Q4 		$146K Buy
68,016
+56,821
+508% +$163K ﹤0.01% 3943
2024
Q3 		$48.7K Buy
+11,195
New +$60.9K ﹤0.01% 4650
2023
Q4 		– Sell
-15,409
Closed -$44.2K – 4940
2023
Q3 		$44.2K Buy
+15,409
New +$56.8K ﹤0.01% 4223
2022
Q1 		– Sell
-27,131
Closed -$145K – 2291
2021
Q4 		$145K Sell
27,131
-11,963
-31% -$83.6K ﹤0.01% 1577
2021
Q3 		$331 Sell
39,094
-58,568
-60% -$578K 0.01% 957
2021
Q2 		$1.19K Buy
+97,662
New +$1.93M 0.04% 384

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Walleye Capital's BDTX Position: Q1 2025 in Review

Walleye Capital sold out of Black Diamond Therapeutics (BDTX) in Q1 2025, closing a stake of 68,016 shares — an estimated $146K sold.

Walleye Capital first reported a position in BDTX in Q2 2021 and held it in 6 quarters. The position peaked at $146K in Q4 2024. 84 funds tracked by Wall St. Rank hold BDTX as of Q1 2025.

  • Walleye Capital reported no remaining Black Diamond Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 68,016 Black Diamond Therapeutics shares in Q1 2025, an estimated $146K.
  • Walleye Capital first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 6 quarters.
  • Walleye Capital's Black Diamond Therapeutics position peaked at $146K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.